Induction of Labor at Term with Oral Misoprostol or as a Vaginal Insert and Dinoprostone Vaginal Insert - A Multicenter Prospective Cohort Study
- PMID: 35967743
- PMCID: PMC9365496
- DOI: 10.1055/a-1860-0419
Induction of Labor at Term with Oral Misoprostol or as a Vaginal Insert and Dinoprostone Vaginal Insert - A Multicenter Prospective Cohort Study
Erratum in
-
Correction: Induction of Labor at Term with Oral Misoprostol or as a Vaginal Insert and Dinoprostone Vaginal Insert - A Multicenter Prospective Cohort Study.Geburtshilfe Frauenheilkd. 2025 Sep 22;85(9):e3. doi: 10.1055/a-2704-9622. eCollection 2025 Sep. Geburtshilfe Frauenheilkd. 2025. PMID: 40989925 Free PMC article.
Abstract
Introduction The efficacy, safety, and perinatal outcome of oral misoprostol (OM), a misoprostol vaginal insert (MVI), and a dinoprostone vaginal insert (DVI) for induction of labor at term was examined in a prospective multicenter cohort study (ethics committee vote 4154-07/14). The primary aims of the study were the induction-birth interval (IBI), the cumulative delivery rates after 12 h, 24 h, and 48 h as well as the mode of delivery. Method 322 pregnant women were included in four German tertiary perinatal centers (MVI 110, DVI 64, OM 148). They did not vary in age or BMI. Statistical analysis was carried out using a multivariate linear regression analysis and binary logistic regression analysis. Results With regards to the median IBI, MVI and OM were equally effective and superior to the DVI (MVI 823 min [202, 5587]; DVI 1226 min [209, 4909]; OM 847 min [105, 5201]; p = 0.006). Within 24 hours, 64% were able to deliver with DVI, 85.5% with MVI and 87.5% with OM (p < 0.01). The rates of secondary Caesarean sections (MVI 24.5%; DVI 26.6%; OM 18.9%) did not differ significantly. Uterine tachysystole was found in 20% with MVI, 4.7% with DVI and 1.4% with OM (p < 0.001). A uterine rupture did not occur in any of the cases. Perinatal acidosis occurred (umbilical cord arterial pH < 7.10) in 8.3% with MVI, 4.7 with DVI and 1% with OM (p = 0.32). Neonatal condition was only impaired in three cases (5-minute Apgar score < 5). Summary Induction of labor at term using the prostaglandins misoprostol and dinoprostone is an effective intervention that is safe for the mother and child. Oral application of misoprostol demonstrated the highest efficacy while maintaining a favorable safety profile.
Keywords: dinoprostone; induction of labor; misoprostol; prostaglandins.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Conflict of interest statement
Conflict of Interest The authors declare that they have no conflict of interest.
References
-
- Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) . Misoprostol in der Frauenheilkunde und Geburtshilfe – Brief an Spahn: große Sorge wegen erschwerten Zugangs zu Cytotec. Geburtshilfe Frauenheilkd. 2021;81:603. doi: 10.1055/a-1495-8331. - DOI
-
- Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) ; Arbeitsgemeinschaft für Geburtshilfe und Pränatalmedizin e. V. (AGG) in der DGGG ; Deutsche Gesellschaft für Perinatale Medizin e. V. (DGPM) ; Deutsche Gesellschaft für Pränatal- und Geburtsmedizin e. V. (DGPGM) ; Bundesarbeitsgemeinschaft Leitender Ärztinnen und Ärzte in der Frauenheilkunde und Geburtshilfe e. V. (BLFG) . Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG) und der Arbeitsgemeinschaft für Geburtshilfe und Pränatalmedizin e. V. (AGG) in der DGGG, der Deutschen Gesellschaft für Perinatale Medizin e. V. (DGPM), der Deutschen Gesellschaft für Pränatal- und Geburtsmedizin e. V. (DGPGM) sowie der Bundesarbeitsgemeinschaft Leitender Ärztinnen und Ärzte in der Frauenheilkunde und Geburtshilfe e. V. (BLFG) zur Berichterstattung über „Cytotec zur Geburtseinleitung“. Geburtshilfe Frauenheilkd. 2020;80:369–370. doi: 10.1055/a-1109-0170. - DOI
LinkOut - more resources
Full Text Sources
